Jane Street
CRVS icon

Jane Street’s Corvus Pharmaceuticals CRVS Stock Holding History

Jane Street’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$651K Sell
44,473
-333,824
-88% -$5.33M ﹤0.01% 7424
2025
Q4 		$2.91M Buy
378,297
+310,231
+456% +$2.45M ﹤0.01% 4097
2025
Q3 		$502K Buy
68,066
+57,948
+573% +$297K ﹤0.01% 7856
2025
Q2 		$40.5K Sell
10,118
-247,685
-96% -$901K ﹤0.01% 9226
2025
Q1 		$820K Buy
257,803
+142,851
+124% +$673K ﹤0.01% 5943
2024
Q4 		$615K Buy
114,952
+64,731
+129% +$483K ﹤0.01% 6336
2024
Q3 		$265K Buy
+50,221
New +$180K ﹤0.01% 8227
2024
Q1 		– Sell
-23,095
Closed -$40.6K – 9310
2023
Q4 		$40.6K Buy
+23,095
New +$33.8K ﹤0.01% 8822
2023
Q3 		– Sell
-35,118
Closed -$80.4K – 8730
2023
Q2 		$80.4K Buy
+35,118
New +$73K ﹤0.01% 8082
2022
Q4 		– Sell
-20,775
Closed -$17K – 9271
2022
Q3 		$17K Buy
+20,775
New +$19.8K ﹤0.01% 9241
2021
Q4 		– Sell
-173,937
Closed -$675K – 10154
2021
Q3 		$842K Buy
+173,937
New +$515K ﹤0.01% 6255

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jane Street's CRVS Position: Q1 2026 in Review

Jane Street reduced its Corvus Pharmaceuticals (CRVS) stake by 88% in Q1 2026, selling an estimated $5.33M and leaving 44,473 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #7424.

Jane Street first reported a position in CRVS in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.91M in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Jane Street held 44,473 shares of Corvus Pharmaceuticals worth $651K as of Q1 2026.
  • Jane Street sold 333,824 Corvus Pharmaceuticals shares in Q1 2026, an estimated $5.33M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7424 holding.
  • Jane Street first reported a position in Corvus Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Jane Street's Corvus Pharmaceuticals position peaked at $2.91M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.